{
    "info": {
        "nct_id": "NCT05552976",
        "official_title": "A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2",
        "inclusion_criteria": "Inclusion Criteria\n\n- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.\n\ni) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.\n\nii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.\n\niii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.\n\n* Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).\n* Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).\n* Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.\n* Participant must have documented disease progression during or after their last antimyeloma regimen.\n\nExclusion Criteria\n\n* Participant who has had prior treatment with mezigdomide or carfilzomib.\n* Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participant must have documented disease progression during or after their last antimyeloma regimen.",
            "criterions": [
                {
                    "exact_snippets": "documented disease progression during or after their last antimyeloma regimen",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during or after last antimyeloma regimen"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.",
            "criterions": [
                {
                    "exact_snippets": "documented diagnosis of multiple myeloma",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.",
            "criterions": [
                {
                    "exact_snippets": "serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain",
                    "criterion": "serum free light chain level (involved light chain)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "an abnormal κ/λ free light chain ratio",
                    "criterion": "κ/λ free light chain ratio",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).",
            "criterions": [
                {
                    "exact_snippets": "must have received prior treatment with lenalidomide",
                    "criterion": "prior treatment with lenalidomide",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 cycles of an anti-CD38 monoclonal antibody (mAb)",
                    "criterion": "prior treatment with anti-CD38 monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible",
                    "criterion": "intolerance to anti-CD38 monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant who has had prior treatment with mezigdomide or carfilzomib.",
            "criterions": [
                {
                    "exact_snippets": "prior treatment with mezigdomide",
                    "criterion": "prior treatment with mezigdomide",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior treatment with ... carfilzomib",
                    "criterion": "prior treatment with carfilzomib",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.",
            "criterions": [
                {
                    "exact_snippets": "Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP)",
                    "criterion": "Myeloma-protein (M-protein) level by serum protein electrophoresis (sPEP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.",
            "criterions": [
                {
                    "exact_snippets": "previously received allogeneic stem cell transplant at any time",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received autologous stem cell transplant within 12 weeks of initiating study treatment",
                    "criterion": "autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).",
            "criterions": [
                {
                    "exact_snippets": "Participant has received at least one prior line of anti-myeloma therapy",
                    "criterion": "prior anti-myeloma therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.",
            "criterions": [
                {
                    "exact_snippets": "M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP)",
                    "criterion": "M-protein in 24-hour urine collection",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": "urine protein electrophoresis (uPEP)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.",
            "criterions": [
                {
                    "exact_snippets": "Participant achieved minimal response or better",
                    "criterion": "response to prior anti-myeloma therapy",
                    "requirements": [
                        {
                            "requirement_type": "response level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "minimal response"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 prior anti-myeloma therapy",
                    "criterion": "number of prior anti-myeloma therapies",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "Exclusion Criteria",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}